ESTRO 2022 - Abstract Book

S1053

Abstract book

ESTRO 2022

Conclusion The initial performance status seems to be the most important predictor of 90 day mortality after chemoradiotherapy. A larger dataset will be constructed to further analyze the influence of the lung V5 on early mortality.

PO-1248 Efficacy of Concurrent Neoadjuvant Chemoradiotherapy in Patients with LA-Non-small-Cell Lung Cancer

C. Greco 1 , A. Iurato 2 , M. Fiore 3 , E. Onorati 3 , E. Molfese 4 , S. Gentile 4 , P. Crucitti 5 , E. Ippolito 4 , S. Ramella 4

1 Campus Bio-Medico University, Radiation Oncology, Rome, Italy; 2 Campus Bio-Medico University, Radiation Oncology, Rome, Italy; 3 Campus Bio-Medico University, Radiation Oncology, Rome, Italy; 4 Campus Bio-Medico University, Radiation Oncology, Rome, Italy; 5 Campus Bio-Medico University, Thoracic Surgery Unit, Rome, Italy Purpose or Objective In LA-NSCLC concurrent neoadjuvant chemoradiotherapy followed by surgery is an established strategy of treatment. The aim of this study is to evaluate efficacy of concurrent chemoradiotherapy followed by surgery in these patients (pts). Materials and Methods Pts with histologically proven NSCLC and medical/functional operability were evaluated. All pts received concurrent neoadjuvant radiochemotherapy followed by surgery. Chemotherapy drugs used included platinum compounds, taxanes, pemetrexed and gemcitabine. Some pts received induction chemotherapy before concurrent radiochemotherapy, using platinum compounds and/or taxanes. RT doses were in the range of 45-70 Gy. Primary end points were OS and DFS.

Results